175 related articles for article (PubMed ID: 10520784)
21. Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin.
Silvain J; O'Connor SA; Yan Y; Kerneis M; Hauguel-Moreau M; Zeitouni M; Overtchouk P; Ankri A; Brugier D; Vicaut E; Ecollan P; Galier S; Collet JP; Montalescot G;
Am J Cardiovasc Drugs; 2018 Dec; 18(6):503-511. PubMed ID: 30144017
[TBL] [Abstract][Full Text] [Related]
22. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.
Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
J Am Coll Cardiol; 1994 Nov; 24(6):1445-52. PubMed ID: 7930274
[TBL] [Abstract][Full Text] [Related]
23. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
[TBL] [Abstract][Full Text] [Related]
24. Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions.
Watkins MW; Luetmer PA; Schneider DJ; Witmer WT; Vaitkus PT; Sobel BE
Cathet Cardiovasc Diagn; 1998 Jul; 44(3):257-64. PubMed ID: 9676792
[TBL] [Abstract][Full Text] [Related]
25. Is the use of unfractionated heparin in acute coronary syndrome outmoded?
Chiquette E; Chilton R
Curr Atheroscler Rep; 2004 Mar; 6(2):94-100. PubMed ID: 15023292
[TBL] [Abstract][Full Text] [Related]
26. The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes.
Bijsterveld NR; Moons AH; Meijers JC; Levi M; Büller HR; Peters RJ
J Am Coll Cardiol; 2003 Aug; 42(3):424-7. PubMed ID: 12906966
[TBL] [Abstract][Full Text] [Related]
27. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Wang XK; Zhang Y; Yang CM; Wang Y; Liu GY
Clin Drug Investig; 2006; 26(6):341-9. PubMed ID: 17163268
[TBL] [Abstract][Full Text] [Related]
28. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
[TBL] [Abstract][Full Text] [Related]
29. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
[TBL] [Abstract][Full Text] [Related]
30. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
Steg PG; Mehta S; Jolly S; Xavier D; Rupprecht HJ; Lopez-Sendon JL; Chrolavicius S; Rao SV; Granger CB; Pogue J; Laing S; Yusuf S
Am Heart J; 2010 Dec; 160(6):1029-34, 1034.e1. PubMed ID: 21146654
[TBL] [Abstract][Full Text] [Related]
31. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial.
Giugliano RP; Wiviott SD; Stone PH; Simon DI; Schweiger MJ; Bouchard A; Leesar MA; Goulder MA; Deitcher SR; McCabe CH; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(25):2398-407. PubMed ID: 17599602
[TBL] [Abstract][Full Text] [Related]
32. Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute cardiac syndromes.
Mungall D; Lord M; Cason S; Treadwell P; Williams D; Tedrick D
Am J Cardiol; 1998 Sep; 82(5):574-9. PubMed ID: 9732882
[TBL] [Abstract][Full Text] [Related]
33. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
[TBL] [Abstract][Full Text] [Related]
34. Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment.
Andersen K; Dellborg M; Emanuelsson H; Grip L; Swedberg K
Coron Artery Dis; 1996 Sep; 7(9):673-81. PubMed ID: 8950498
[TBL] [Abstract][Full Text] [Related]
35. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
Antman EM
Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
[TBL] [Abstract][Full Text] [Related]
36. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes.
Melloni C; Alexander KP; Chen AY; Newby LK; Roe MT; Allen LaPointe NM; Pollack CV; Gibler WB; Ohman EM; Peterson ED;
Am Heart J; 2008 Aug; 156(2):209-15. PubMed ID: 18657648
[TBL] [Abstract][Full Text] [Related]
37. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
[TBL] [Abstract][Full Text] [Related]
38. [Non-ST elevation acute coronary syndrome: changes of parameters of hemostasis during and after treatment with unfractionated heparin and enoxaparin].
Averkov OV; Slavina NN; Dobrovol'skiĭ AB; Gratsianskiĭ NA
Kardiologiia; 2003; 43(9):28-40. PubMed ID: 14593367
[TBL] [Abstract][Full Text] [Related]
39. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
Montalescot G; Bal-dit-Sollier C; Chibedi D; Collet JP; Soulat T; Dalby M; Choussat R; Cohen A; Slama M; Steg PG; Dubois-Randé JL; Metzger JP; Tarragano F; Guermonprez JL; Drouet L;
Am J Cardiol; 2003 Apr; 91(8):925-30. PubMed ID: 12686329
[TBL] [Abstract][Full Text] [Related]
40. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Granger CB; Becker R; Tracy RP; Califf RM; Topol EJ; Pieper KS; Ross AM; Roth S; Lambrew C; Bovill EG
J Am Coll Cardiol; 1998 Mar; 31(3):497-505. PubMed ID: 9502626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
